Combined blood markers correctly detect early pancreatic cancer in human cancer cells
A newly identified biomarker panel could pave the way to earlier detection and better treatment for pancreatic cancer, according to new research from the Perelman School of Medicine at University of Pennsylvania. Currently over 53,000 people in the United States are diagnosed with pancreatic cancer — the fourth leading cause of cancer death — every year. The blood biomarkers, detailed today in Science Translational Medicine, correctly detected pancreatic cancer in blood samples from patients at different stages of their disease.
The majority of pancreatic cancer patients are not diagnosed until an advanced stage, beyond the point at which their tumors can be surgically removed.
A team led by Ken Zaret, PhD, director of the Penn Institute for Regenerative Medicine and the Joseph Leidy Professor of Cell and Developmental Biology, and Gloria Petersen, PhD, from the Mayo Clinic, identified a pair of biomarkers that physicians could soon use to discover the disease earlier.
“Starting with our cell model that mimics human pancreatic cancer progression, we identified released proteins, then tested and validated a subset of these proteins as potential plasma biomarkers of this cancer,” Zaret said. The authors anticipate that health care providers will use the early-detection biomarkers to test for their presence and levels in blood from pancreatic cancer patients and blood drawn from individuals with a high risk of developing pancreatic cancer, including those who have a first-degree relative with pancreatic cancer, are genetically predisposed to the disease, or who had a sudden onset of diabetes after the age of 50.
“Early detection of cancer has had a critical influence on lessening the impact of many types of cancer, including breast, colon, and cervical cancer. A long standing concern has been that patients with pancreatic cancer are often not diagnosed until it is too late for the best chance at effective treatment,” said Robert Vonderheide, MD, DPhil, director of the Abramson Cancer Center (ACC) at the University of Pennsylvania. “Having a biomarker test for this disease could dramatically alter the outlook for these patients.”
Novel method for discovering pancreatic cancer biomarkers
Credit: The lab of Ken Zaret, Perelman School of Medicine, University of Pennsylvania
The biomarker panel, enabled by discovery work of first author Jungsun Kim, PhD, a postdoctoral fellow in Zaret’s lab, builds on a first-of-its-kind human-cell model of pancreatic cancer progression the lab described in 2013. They used stem-cell technology to create a cell line from a patient with advanced pancreatic ductal adenocarcinoma. Genetically reprogramming late-stage human cancer cells to a stem-cell state enabled them to force the reprogrammed cells to progress to an early cancerous state, revealing secreted blood biomarkers of early-stage disease along the way.
The best candidate biomarker, plasma thrombospondin-2 (THBS2), was screened against 746 cancer and control plasma samples using an inexpensive, commercially available protein-detection assay. The team found that blood levels of THBS2, combined with levels of a known later-stage biomarker called CA19-9, was reliable at detecting the presence of pancreatic cancer in patients.
The team refined the assay with independent investigations of plasma samples from patients with different stages of cancer, from individuals with benign pancreatic disease, and from healthy controls, all obtained from Petersen, who directs the biospecimen resource program for pancreas research at the Mayo Clinic.
“Positive results for THBS2 or CA19-9 concentrations in the blood consistently and correctly identified all stages of the cancer,” Zaret said. “Notably, THBS2 concentrations combined with CA19-9 identified early stages better than any other known method.” The combination panel also improved the ability to distinguish cases of cancer from pancreatitis. The panel will next be validated in a set of samples from pancreatic cancer patients who provided a research blood sample prior to their diagnosis.
The Latest on: Pancreatic cancer
- “Pancreas in a Dish” Tells Story of How Metastatic Cells Turn Back Time on July 27, 2017 at 12:30 pm
To trace the cause of metastasis in pancreatic cancer, the CSHL team used cells sampled from six mice to grow paired sets of pancreatic organoids—balls of cells that develop in 3D culture. The mice had gene mutations that induced pancreatic ductal cancer. […]
- New SU2C-Lustgarten Foundation team aims to apply CAR T-cell therapy to pancreatic cancer on July 27, 2017 at 11:15 am
PHILADELPHIA – July 27, 2017 – Stand Up To Cancer is supporting a new translational research team to explore how a type of immunotherapy that has been very successful in blood cancers can be applied to pancreatic cancer, the American Association for ... […]
- Husband and wife team develop 'holy grail' drug to battle pancreatic cancer on July 27, 2017 at 11:02 am
Bianca Sams was allegedly punched in the face by a 44-year-old man with police now claiming she threw objects at him. Amazon founder Jeff Bezos on Thursday became the world's richest person, as a jump in the share price of the US tech giant enabled him to ... […]
- Mechanism of metastasis is discovered in pancreatic cancer on July 27, 2017 at 9:32 am
WOODBURY, N.Y., July 27, 2017 /PRNewswire-USNewswire/ -- Lustgarten Foundation funded research discovered a mechanism of metastasis in pancreatic cancer, and perhaps, other cancer types as well. The Foundation's dedicated lab at Cold Spring Harbor ... […]
- Long-sought mechanism of metastasis is discovered in pancreatic cancer on July 27, 2017 at 9:02 am
To trace the cause of metastasis in pancreatic cancer, the CSHL team used cells sampled from six mice to grow paired sets of pancreatic organoids -- balls of cells that develop in 3-D culture. The mice had gene mutations that induced pancreatic ductal cancer. […]
- How a sponge could cure pancreatic cancer - would you recognise symptoms of the disease? on July 27, 2017 at 6:40 am
Pancreatic cancer symptoms can be hard to spot - which is one of the reasons it's known as a silent killer. The disease is one of the most deadly cancers in the UK. Now experts have revealed all green sponge discovered off the coast of Alaska could be used ... […]
- Small sea sponge holds big promise against pancreatic cancer on July 27, 2017 at 12:27 am
WASHINGTON – A small dull-green sponge discovered in dark, icy waters of the Pacific off Alaska could be the first effective weapon against pancreatic cancer, researchers said Wednesday. Pancreatic cancer, with particularly aggressive tumors, is ... […]
- Small green sponge found in the icy waters off Alaska could CURE pancreatic and ovarian cancer on July 26, 2017 at 5:46 pm
A golf-sized green sponge discovered more than a decade ago in deep, icy waters off the coast of Alaska is showing promise as a treatment for pancreatic and ovarian cancer. Scientists say a molecule from the sponge selectively killed malignant cells in ... […]
- Could green sponge found near Alaska hold key to curing pancreatic cancer? on July 25, 2017 at 9:00 pm
Could green sponge found near Alaska hold key to curing pancreatic cancer? Scientists say a green sponge discovered in deep waters off the coast of Alaska is showing promise as a potential treatment for pancreatic cancer. Check out this story on Freep.com ... […]
- Pancreatic cancer experts on July 25, 2017 at 5:03 pm
Your care team meets each week to discuss the progression of your treatment as it relates to your specific medical, nutritional, emotional and spiritual needs. This allows our pancreatic cancer experts to share in your progress and improve the quality of ... […]
via Google News and Bing News